Cargando…

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival

BACKGROUND: KRAS mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era with immunotherapy as a dominant treatment option in metastatic NSCLC,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amanam, Idoroenyi, Mambetsariev, Isa, Gupta, Rohan, Achuthan, Srisairam, Wang, Yingyu, Pharaon, Rebecca, Massarelli, Erminia, Koczywas, Marianna, Reckamp, Karen, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article on Role of Precision Imaging in Thoracic Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578487/ https://www.ncbi.nlm.nih.gov/pubmed/33145085 http://dx.doi.org/10.21037/jtd.2020.04.18

Ejemplares similares

Biomarkers in immunotherapy: literature review and future directions
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma
por: Gupta, Rohan, et al.
Publicado: (2019)

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Precision medicine and actionable alterations in lung cancer: A single institution experience
por: Mambetsariev, Isa, et al.
Publicado: (2020)

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2021)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
por: Baroz, Angel R, et al.
Publicado: (2021)

Utility and efficacy of advanced imaging in thoracic disorders
por: Chaudhry, Ammar
Publicado: (2020)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Role of precision imaging in esophageal cancer
por: Elsherif, Sherif B., et al.
Publicado: (2020)

Role of cardiac nuclear stress perfusion exam after computed tomographic coronary angiogram for evaluation of obstructive coronary artery disease in patients with chest pain
por: Gul, Maryam, et al.
Publicado: (2020)

Refining dataset curation methods for deep learning-based automated tuberculosis screening
por: Kim, Tae Kyung, et al.
Publicado: (2020)

Thyroid cancer diagnosis in the era of precision imaging
por: Bonjoc, Kimberley-Jane, et al.
Publicado: (2020)

Thoracic imaging finding of rheumatic diseases
por: Gul, Maryam, et al.
Publicado: (2020)

Keratin 17 is an imaging biomarker in lung cancers
por: Bhattacharji, Priya, et al.
Publicado: (2020)

Role of imaging in lung transplantation evaluation
por: Calvert, Alexander D., et al.
Publicado: (2020)

Role of theranostics in thoracic oncology
por: Filippov, Aleksandr, et al.
Publicado: (2020)

Radiogenomics of lung cancer
por: Wong, Chi Wah, et al.
Publicado: (2020)

Integration of artificial intelligence in lung cancer: Rise of the machine
por: Ladbury, Colton, et al.
Publicado: (2023)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2022)

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
por: Roosan, Moom R., et al.
Publicado: (2021)

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
por: Rajurkar, Swapnil, et al.
Publicado: (2020)

Targeted Therapies for Pancreatic Cancer
por: Amanam, Idoroenyi, et al.
Publicado: (2018)

Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells
por: Mirzapoiazova, Tamara, et al.
Publicado: (2019)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS
por: Kalvala, Arjun, et al.
Publicado: (2019)

Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression
por: Reyes, Amanda, et al.
Publicado: (2022)

Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
por: Reyes, Amanda, et al.
Publicado: (2023)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
por: Mohanty, Atish, et al.
Publicado: (2023)

81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML
por: Jones, LaQuita, et al.
Publicado: (2021)

Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report
por: Roth, Katherine G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d0ivc8o6r524h50ge1ceoi6el9